TY - JOUR
T1 - Employment, Work Productivity, and Biologic Treatments in Self-Reported Axial Spondyloarthritis
T2 - a Cross-Sectional Study in a Female Predominant Population from the ArthritisPower Registry
AU - Gavigan, Kelly
AU - Nowell, W. Benjamin
AU - Hunter, Theresa
AU - Curtis, Jeffrey R.
AU - Malatestinic, William N.
AU - Bolce, Rebecca J.
AU - Lisse, Jeffrey R.
AU - Walsh, Jessica
N1 - Funding Information:
Kelly Gavigan has no personal conflicts of interests to disclose and is an employee of the Global Healthy Living Foundation (GHLF). William B Nowell is the Principal Investigator on grants/contracts from AbbVie, Eli Lilly and Company, and PCORI, and an employee of the GHLF. GHLF receives grants, sponsorships, and contracts from pharmaceutical manufacturers and private foundations. A full list of GHLF funders is publicly available here: https://www.ghlf.org/our-partners/ . Theresa Hunter, William Malatestinic, Rebecca Bolce, and Jeffrey Lisse are employees and shareholders of Eli Lilly and Company. Jeffrey R Curtis receives grants and personal fees from AbbVie, Amgen, BMS, Corrona, Eli Lilly and Company, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, and receives personal fees from Gilead, Novartis, and Samsung. Jessica A Walsh receives grants from AbbVie, Merck, and Pfizer, and has received personal fees from AbbVie, Amgen, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB.
Funding Information:
This study and journal’s Rapid Service Fee was sponsored by Eli Lilly and Company. This work was partially supported through a Patient-Centered Outcomes Research Institute (PCORI) award (PPRN-1306-04811). All statements in this manuscript, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the PCORI, its Board of Governors, or Methodology Committee.
Funding Information:
The authors wish to thank Jennifer Walker for her assistance in study conceptualization and design. The authors also wish to thank Laura Stradford for her help in planning and implementing the study, and participants of ArthritisPower registry for their time and willingness to participate in this study. This study and journal?s Rapid Service Fee was sponsored by Eli Lilly and Company. This work was partially supported through a Patient-Centered Outcomes Research Institute (PCORI) award (PPRN-1306-04811). All statements in this manuscript, including its findings and conclusions, are solely those of the authors and do not necessarily represent the views of the PCORI, its Board of Governors, or Methodology Committee. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Conception of the work: Kelly Gavigan (KG), W Benjamin Nowell (WBN), Theresa Hunter (TH), William N Malatestinic (WNM), Jessica A Walsh (JAW). Design of the work: KG, WBN, TH, Jeffrey R Curtis (JRC), WMN, Rebecca J. Bolce (RJB), Jeffrey R. Lisse (JRL), JAW. Acquisition of data for the work: KG, WBN. Analysis of data for the work: KG, WBN. Interpretation of data for the work: KG, WBN, TH, JRC, WMN, RJB, JRL, JAW. Drafting of manuscript: KG, WBN, TH, JAW. Critical revision of manuscript for important intellectual content: KG, WBN, TH, JRC, WMN, RJB, JRL, JAW. This manuscript is based on work that was previously published as an abstract at the American College of Rheumatology conference in November 2020. Kelly Gavigan has no personal conflicts of interests to disclose and is an employee of the Global Healthy Living Foundation (GHLF). William B Nowell is the Principal Investigator on grants/contracts from AbbVie, Eli Lilly and Company, and PCORI, and an employee of the GHLF. GHLF receives grants, sponsorships, and contracts from pharmaceutical manufacturers and private foundations. A full list of GHLF funders is publicly available here:?https://www.ghlf.org/our-partners/. Theresa Hunter, William Malatestinic, Rebecca Bolce, and Jeffrey Lisse are employees and shareholders of Eli Lilly and Company. Jeffrey R Curtis receives grants and personal fees from AbbVie, Amgen, BMS, Corrona, Eli Lilly and Company, Janssen, Myriad, Pfizer, Regeneron, Roche, and UCB, and receives personal fees from Gilead, Novartis, and Samsung. Jessica A Walsh receives grants from AbbVie, Merck, and Pfizer, and has received personal fees from AbbVie, Amgen, Eli Lilly and Company, Janssen, Novartis, Pfizer, and UCB. This study has received an exempt determination from Advarra Institutional Review Board, stating that the study is exempt from IRB oversight. This study was performed in accordance with the Helsinki Declaration of 1964, and its later amendments. All subjects provide informed consent to participate in the study. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/4
Y1 - 2022/4
N2 - Introduction: The aim of this study was to characterize employment, work productivity, and biologic disease-modifying anti-rheumatic drug (bDMARD) treatment in a predominantly female population of axial spondyloarthritis (axSpA) patients in a real-world setting. Methods: This was a cross-sectional study of axSpA participants within the ArthritisPower registry. Outcomes were assessed with surveys (Work Productivity and Activity Impairment [WPAI], Bath Ankylosing Spondylitis Disease Activity Index [BASDAI], and Patient-Reported Outcomes Measurement Information System instruments) and compared between subgroups (employed vs. not employed; taking vs. not taking a bDMARD). Results: Among the 195 participants, 117 (60.0%) were employed and 78 (40.0%) were not employed entirely or partially due to axSpA. The mean age of the participants was 47.6 years and 86.7% were female. Current bDMARD use was reported by 57.4% of those surveyed (59.8% employed vs. 53.9% not employed; p = 0.408). Compared to not employed participants, employed participants had more favorable disease activity (BASDAI 6.0 vs. 7.6; p < 0.001) and overall health (self-rated health 2.5 vs. 1.8; p < 0.001). Employed participants, compared to not employed participants, were diagnosed at an earlier age (36.0 vs. 42.5 years, respectively) and experienced a shorter time between symptom onset and diagnosis (9.5 vs. 13.6 years, respectively). Employed participants reported missing on average 6.5 days of work and experienced a 52.7% impairment on work productivity due to axSpA over a 3-month period. Absenteeism and presenteeism were statistically similar between participants taking a bDMARD versus those not taking a bDMARD. Conclusions: Although bDMARD treatment rates were similar between employed and not employed participants, disease activity and overall health were better in employed than non-employed participants. Employed participants experienced substantial work productivity impairment due to axSpA.
AB - Introduction: The aim of this study was to characterize employment, work productivity, and biologic disease-modifying anti-rheumatic drug (bDMARD) treatment in a predominantly female population of axial spondyloarthritis (axSpA) patients in a real-world setting. Methods: This was a cross-sectional study of axSpA participants within the ArthritisPower registry. Outcomes were assessed with surveys (Work Productivity and Activity Impairment [WPAI], Bath Ankylosing Spondylitis Disease Activity Index [BASDAI], and Patient-Reported Outcomes Measurement Information System instruments) and compared between subgroups (employed vs. not employed; taking vs. not taking a bDMARD). Results: Among the 195 participants, 117 (60.0%) were employed and 78 (40.0%) were not employed entirely or partially due to axSpA. The mean age of the participants was 47.6 years and 86.7% were female. Current bDMARD use was reported by 57.4% of those surveyed (59.8% employed vs. 53.9% not employed; p = 0.408). Compared to not employed participants, employed participants had more favorable disease activity (BASDAI 6.0 vs. 7.6; p < 0.001) and overall health (self-rated health 2.5 vs. 1.8; p < 0.001). Employed participants, compared to not employed participants, were diagnosed at an earlier age (36.0 vs. 42.5 years, respectively) and experienced a shorter time between symptom onset and diagnosis (9.5 vs. 13.6 years, respectively). Employed participants reported missing on average 6.5 days of work and experienced a 52.7% impairment on work productivity due to axSpA over a 3-month period. Absenteeism and presenteeism were statistically similar between participants taking a bDMARD versus those not taking a bDMARD. Conclusions: Although bDMARD treatment rates were similar between employed and not employed participants, disease activity and overall health were better in employed than non-employed participants. Employed participants experienced substantial work productivity impairment due to axSpA.
KW - Ankylosing spondylitis
KW - Axial spondyloarthritis
KW - Employment
KW - Female population
KW - Work productivity
UR - http://www.scopus.com/inward/record.url?scp=85125247038&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125247038&partnerID=8YFLogxK
U2 - 10.1007/s40744-022-00428-x
DO - 10.1007/s40744-022-00428-x
M3 - Article
AN - SCOPUS:85125247038
SN - 2198-6576
VL - 9
SP - 663
EP - 677
JO - Rheumatology and Therapy
JF - Rheumatology and Therapy
IS - 2
ER -